# POST-CABGDM: Empagliflozin in Perioperative CABG

Study · id `cardio:ct-nct04523064` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04523064](<https://clinicaltrials.gov/study/NCT04523064>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04523064

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.

## Technical summary

Registry record NCT04523064. Randomized; no masking; primary purpose treatment. Start 2020-09-22 (actual); primary completion 2024-01-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 155 participants (enrolled count; ClinicalTrials.gov record NCT04523064, source copy `cardio:ctgov-nct04523064-2024-06-10`, retrieved 2026-11-18)
- Started: 2020-09-22 (actual) (ClinicalTrials.gov record NCT04523064, source copy `cardio:ctgov-nct04523064-2024-06-10`, retrieved 2026-11-18)
- Primary completion: 2024-01-30 (actual) (ClinicalTrials.gov record NCT04523064, source copy `cardio:ctgov-nct04523064-2024-06-10`, retrieved 2026-11-18)
- Completion: 2024-01-30 (actual) (ClinicalTrials.gov record NCT04523064, source copy `cardio:ctgov-nct04523064-2024-06-10`, retrieved 2026-11-18)
- Countries: Brazil (ClinicalTrials.gov record NCT04523064, source copy `cardio:ctgov-nct04523064-2024-06-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04523064-2024-06-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: POST-CABGDM: Empagliflozin in Perioperative CABG
- Acronym: POST-CABGDM
- Condition: Diabetes Mellitus, Type 2
- Condition: Coronary Artery Disease
- Condition: Coronary Artery Bypass Surgery
- Condition: Acute Kidney Injury
- Intervention (Drug): Empagliflozin 25 MG
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)

## Provenance

Content hash: d8b5a84f684ef7d0b7a980f41bda1452d4a4236deb26b2437ff962821b6d1b41
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
